Efektivitas Efikasi Pemberian Antivirus Favipiravir pada Pasien Covid-19: Evidence Based Case Report
DOI:
Abstract Views:
1186 times
PDF Downloads:
1044 times
Abstract
Abstract—COVID-19 pandemic is still a major global health problem. Currently, there are no specific treatment recommendations for Covid-19 patients. Currently, the number of studies discussing antiviral therapy is increasing, but the efficacy of giving antiviral to Covid-19 patients is still being debated. Favipiravir is an antiviral regimen that is widely used to treat moderate to severe Covid-19 patients. This report aims to identify how effective Favipiravir in Covid-19 patients. Literature searching was carried in four internet databases, including Pubmed, Scopus, EBSCO, and Cochrane Library based on inclusion and exclusion criteria. The validity, importance, and applicability of the article is the further examined. The article under review should have the same problems, interventions, and outcomes as the case. There were three selected meta-analysis studies that were equally valid and applicable to our patients. Study from Manabe show OR = 1.60, 95% CI = 1.03–2.40, p = 0.04. Study from Hassanipour show RR= 1.24, 95% CI: 1.09–1.41; p= 0.001. Study from Shrestha show RR = 1.25. 95% CI = 1.01-1.53, p = 0.01. Administration of Favipiravir as an antiviral in the treatment of Covid-19 patients can reduce viral load faster and provide better clinical improvement.
Keywords: covid-19, effectiveness efficacy, favipiravir
Abstrak—Pandemi COVID-19 masih menjadi permasalahan utama kesehatan dunia. Saat ini belum tersedia rekomendasi tatalaksana khusus pasien Covid-19. Jumlah studi yang membahas mengenai terapi antivirus semakin bertambah, namun efikasi pemberian terapi antivirus pada pasien Covid-19 masih menjadi perdebatan. Favipiravir merupakan regimen antivirus yang banyak digunakan sebagai tatalaksana pasien Covid-19 derajat sedang sampai berat. Laporan ini bertujuan untuk mengidentifikasi bagaimana efektivitas efikasi Favipiravir pada pasien Covid-19. Penelusuran literatur dilakukan pada empat database internet yaitu Pubmed, Scopus, EBSCO dan Cochrane library berdasarkan kriteria inklusi dan eksklusi. Validitas, Kepentingan dan Aplikabilitas artikel kemudian ditelaah lebih lanjut. Artikel yang ditelaah harus memiliki masalah, intervensi dan outcome yang sama dengan kasus. Terdapat tiga studi meta-analysis terpilih yang memiliki validitas yang sama dan dapat diterapkan pada pasien kami. Studi oleh Manabe didapatkan OR = 1,60, 95% CI = 1,03–2,40, p = 0,04. Studi oleh Hassanipour didapatkan RR= 1,24, 95% CI = 1,09–1,41, p= 0,001. Studi oleh Shrestha didapatkan RR = 1,25, 95% CI = 1,01-1,53, p = 0,01. Pemberian Favipiravir sebagai antivirus dalam pengobatan pasien Covid-19 dapat menurunkan viral load lebih cepat dan memberikan perbaikan klinis yang lebih baik.
Kata kunci: covid-19, efektivitas efikasi, favipiravir
Downloads
References
Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75(7):2013–4.
Eroglu E, Toprak C. Overview of favipiravir and remdesivir treatment for COVID-19. Int J Pharm Sci Res. 2021;12(4):1950–7.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10):1192–8.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Vol 102, International Journal of Infectious Diseases. International Society for Infectious Diseases; 2021. 501–508 bl.
Prakash A, Singh H, Kaur H, Semwal A, Sarma P, Bhattacharyya A, et al. Systematic review and meta-Analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020;52(5):414–21.
Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D. Favipiravir for treating patients with novel coronavirus (COVID-19): Protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open. 2020;10(7):1–3.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv. 2020;
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1–13.
Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):1–11.
Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17(1):141.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Articles published in Keluwih: JKK are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to Kluwih: JKK to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in Keluwih: JKK, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
